Edward J. Brennan - 31 Dec 2024 Form 3 Insider Report for Medicus Pharma Ltd. (MDCX)

Role
Chief Scientific Officer
Signature
/s/ James Quinlan, as Attorney-in-Fact, for Edward J. Brennan
Issuer symbol
MDCX
Transactions as of
31 Dec 2024
Net transactions value
$0
Form type
3
Filing time
31 Dec 2024, 16:05:19 UTC
Next filing
24 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MDCX Common Shares, no par value ("Common Shares") 86,500 31 Dec 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MDCX Stock Option (right to buy) 31 Dec 2024 Common Shares 75,000 $0.8100 Direct F1, F2
holding MDCX Stock Option (right to buy) 31 Dec 2024 Common Shares 20,000 $2.75 Direct F3, F4
holding MDCX Warrants (right to buy) 31 Dec 2024 Common Shares 24,000 $4.64 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option has vested and is exercisable as of the date hereof.
F2 Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
F3 The option was granted on December 17, 2024. The option is scheduled to vest quarterly in four equal installments over one year.
F4 Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
F5 The warrants are exercisable as of the date hereof.

Remarks:

Exhibit List - Exhibit 24.1 - Power of Attorney